NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Account Payables
Amounts the company owes suppliers for goods and services received.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 2.0% from a year ago
Account payables stood at $4.4M at the end of Q1 FY2026, up 2.0% from a year earlier and up 3.0% from the prior quarter. Over 3 fiscal years it compounded at +27.2% a year.
Context
- Account payables amounted to 37.0% of total assets at the end of Q1 FY2026, down 19.8 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +2.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 4.27M USD
- Year-over-year change
- +3.4%
- 4-year CAGR
- +3.7%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.27M | +3.4% |
| FY2024 | 2024-12-31 | 4.13M | -10.8% |
| FY2023 | 2023-12-31 | 4.63M | +123.1% |
| FY2022 | 2022-12-31 | 2.08M | -43.7% |
| FY2021 | 2021-12-31 | 3.69M | — |
Account Payables vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 account payables of $4.4M is the 2nd highest of the 9 companies compared; the peer median is $2.92M.
- Its year-over-year change of +2.0% is the 3rd highest of 9, against a peer median of -12.0%.
- Account payables amounts to 37.0% of total assets for NRXP, versus a peer median of 4.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $13.64M | +75.6% | +42.9% | 62.3% | |
| Mar 2026 | $4.4M | +2.0% | +27.2% | 37.0% | |
| Mar 2026 | $4.28M | -27.1% | +13.0% | 3.3% | |
| Mar 2026 | $3.33M | -12.1% | +13.1% | 10.8% | |
| Mar 2026 | $3.15M | -11.8% | -4.3% | 1.0% | |
| Mar 2026 | $2.68M | +42.8% | -12.9% | 4.8% | |
| Jun 2026 | $1.94M | -30.1% | -14.8% | 8.0% | |
| Mar 2026 | $1.3M | -57.7% | -42.5% | 2.1% | |
| Mar 2026 | $1.01M | -9.8% | +107.8% | 5.1% | |
| Peer median (excluding NRXP) | $2.92M | -12.0% | +4.3% | 4.9% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.